Scarica l'app Stockscreener
1.65
7.82%
-0.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.79
Aprire:
$1.72
Volume 24 ore:
454.75K
Relative Volume:
1.86
Capitalizzazione di mercato:
$45.85M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-1.50
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
-12.70%
1M Prestazione:
-14.95%
6M Prestazione:
-9.34%
1 anno Prestazione:
-53.91%
Intervallo 1D:
$1.56
$1.8004
Intervallo di 1 settimana:
$1.56
$1.99
Portata 52W:
$0.89
$3.72
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.65 | 45.85M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Average Price Target from Analysts - Defense World
Roth Capital Issues Optimistic Estimate for GANX Earnings - Defense World
Q1 Earnings Forecast for GANX Issued By Roth Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Chardan Capital Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Optimistic Buy Rating for Gain Therapeutics Driven by Promising GT-02287 Developments and Stable Financial Position - TipRanks
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call - The Manila Times
New Clinical Trial Details: Gain's Innovative Parkinson's Treatment Heads to Major Conference - Stock Titan
Gain Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Gain Therapeutics Inc. (GANX) reports earnings - Quartz
Gain Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update - The Manila Times
Breakthrough: Gain Therapeutics' Parkinson's Treatment Achieves 50% Activity Increase in Clinical Trial - Stock Titan
Best Momentum Stocks to Buy for January 9th - MSN
First Parkinson’s patient dosed in GT-02287 clinical trial - Parkinson's News Today
European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World
Gain Therapeutics (GANX) to Release Quarterly Earnings on Tuesday - Defense World
Enzolytics, Inc. (OTCMKTS:ENZC) Sees Large Decrease in Short Interest - Defense World
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 24.5% - Defense World
Scotiabank Initiates Coverage of Gain Therapeutics (GANX) with Sector Outperform Recommendation - MSN
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease - IT Business Net
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - openPR
Gain Therapeutics Doses First Participant In Phase 1b Trial Of GT-02287 For Parkinson's Disease - Nasdaq
Gain Therapeutics Begins Dosing Parkinson's Patients in GT-02287 Study -March 14, 2025 at 08:29 am EDT - Marketscreener.com
Gain Therapeutics Initiates Dosing in Phase 1b Clinical Trial for Parkinson's Disease Treatment GT-02287 - Nasdaq
Jones Financial Companies Lllp Purchases 44,750 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Seres Therapeutics, Inc. SEC 10-K Report - TradingView
Parkinson's Disease Clinical Pipeline | 130+ Companies Advancing the Future of Treatment - openPR
Ono earmarks $940m to gain rare blood cancer therapy from Ionis - Yahoo
Closing Figures Unveiled: Dave Inc (DAVE) Gain 0.18, Closes at 83.36 - The Dwinnex
Gain Therapeutics (NASDAQ:GANX) Research Coverage Started at Scotiabank - Defense World
Sun Pharma Shares Gain 2% on Plans to Acquire Checkpoint Therapeutics - EquityPandit
Analysts Set Gain Therapeutics, Inc. (NASDAQ:GANX) PT at $8.20 - Defense World
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know - MSN
Scotiabank starts Gain Therapeutics stock with $12 target - Investing.com
Scotiabank starts Gain Therapeutics stock with $12 target By Investing.com - Investing.com UK
Gain Therapeutics initiated with an Outperform at Scotiabank - TipRanks
Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - The Manila Times
Gain Therapeutics, Inc. to Present Clinical Stage Drug Candidate GT-02287 at AD/PD™ 2025 Conference in Vienna - Nasdaq
Can This New Drug Candidate Transform Parkinson's Disease Treatment? Key Data Coming - Stock Titan
Pre-market Movers: PRFX, BJDX, TARA, PBM... - RTTNews
Investing in Zevra Therapeutics (NASDAQ:ZVRA) five years ago would have delivered you a 83% gain - Yahoo Finance
Top Trend In Retinal Vein Occlusion Market 2025: Pioneering Innovations In The Retinal Vein Occlusion Marke... - WhaTech
OPKO HEALTH, INC. SEC 10-K Report - TradingView
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry - Simply Wall St
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo Finance
Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales - MSN
GAIN THERAPEUTICS: A Microcap Stock to Love - substack.com
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
MSSM's Underlying Holdings Imply 19% Gain Potential - Nasdaq
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):